NorthStar is an emerging leader with new solutions in the field of nuclear medicine technology
NorthStar Medical Radioisotopes, LLC is a privately held nuclear medicine technology company committed to providing reliable and environmentally friendly radioisotope supply solutions to meet patient needs and advance clinical research. Founded in 2006 and based in Beloit, Wisconsin, NorthStar is a wholly-owned subsidiary of NorthStar Medical Technologies, LLC.
NorthStar leadership recognized the challenges that nuclear medicine faces in securing domestic and reliable radioisotope production. To meet this and other unmet industry needs, NorthStar initially obtained exclusive access to certain worldwide patents through a licensing agreement with PG Research Foundation1. NorthStar continues to build a robust patent portfolio of innovative technologies, both from internally developed and externally licensed intellectual property. These patented technologies, which have worldwide scope, contain methods and instrumentation to solve many of the challenges associated with ultrapure radioisotope production, and include numerous separable market applications.
NorthStar is deploying the initial application of this technology with the RadioGenix® System (technetium Tc 99m generator), an innovative, high-tech radioisotope separation platform, recently approved by the U.S. Food and Drug Administration. The Company aims to create and deploy novel radioisotope production technologies, instrumentation and associated disposables for radionuclide separation for commercial and academic suppliers of radiopharmaceuticals throughout the United States.
NorthStar is engaged in providing the newest radioisotopes in quantities sufficient to meet the needs of today’s researchers and tomorrow’s pharmaceutical developers. In parallel, the Company intends to set new standards for safety, purity and dose consistency.
1PGRF, the PG Research Foundation Inc., located in Lisle, IL, is a technology development company with deep expertise in chemical separations and significant experience in separating nuclear isotopes. Its founder, E. Phil Horwitz, is a retired Senior Scientist of Argonne National Laboratory in Argonne, IL with a distinguished career in this area of science.
Our people drive our solutions, and we are committed
We are committed to advancing radioisotope technology
We are committed to quality and safety as our number one priorities.
We are committed to meeting the healthcare needs of patients by providing U.S. radiopharmacies with reliable, domestic and non-uranium based medical isotope supply.
We are committed to reducing the U.S. healthcare system’s reliance on fragile, foreign medical isotope supply while helping to manage the ever-growing costs of diagnostic testing.
We are committed to ensuring that our processes and products are environmentally friendly.
We are committed to advancing clinical research through production of diagnostic and therapeutic radioisotopes to address unmet medical needs.
Transforming Medical Radioisotopes
To be the recognized global leader of innovative diagnostic and therapeutic medical radioisotopes